Zepbound

Latest three-month snapshot through 2026-08-05 · 1 wave. Use the controls above to change the window.

GLP-1 Medications · 1 wave · n=72 answers, pooled

By model

How often each model brings the brand up in recommendation answers.

Share of recommendations over time

Wave-by-wave share of recommendation answers that named this brand.

What they call it

Recurring descriptions in the models' own words, grouped by theme.

• fda-approved for weight management ×32

  “* **FDA Approval:** Zepbound is specifically FDA-approved for chronic weight management (for adults with obesity, or those who are overweight with at least one weight-related condition).”

• weekly dosing ×29

  “They are administered as a weekly injection, have the same side effects, and come in the exact same doses (ranging from 2.”

• dual gip/glp-1 agonist ×25

  “If you are looking to lose weight, **Zepbound (tirzepatide)** is the superior choice by a wide margin.”

• greater weight loss ×25

  “Zepbound (injectable): ~22.5% average weight loss.”

• fda-approved ×18

  “Because they are FDA-approved for entirely different medical conditions, choosing the wrong one could mean your insurance won't cover it or you won't get the specific health benefits you need.”

• tirzepatide ×17

  “If you are eligible for either and the deciding goal is **the greatest average weight loss**, choose Zepbound (tirzepatide).”

• once-weekly injection ×14

  “Newer, once-weekly injections are generally more effective for weight loss than Saxenda and may end up being cheaper depending on your insurance or manufacturer savings cards.”

• chronic weight management ×11

  “If you do not have Type 2 diabetes and your goal is chronic weight management, **Zepbound** is the correct choice.”

• most effective weight-loss medications ×10

  “Patients lose an average of **20%+ of their body weight**. Wegovy and Zepbound only require **once-weekly** injections.”

• injectable option ×9

  “* **Excellent for Weight Maintenance:** If you have already lost weight using highly potent injectable GLP-1s (like Wegovy or Zepbound) but want to transition off weekly shots, clinical trials (such as the *ATTAIN-MAINTAIN* trial) show that switching to Foundayo is highly effecti”

In their words

243 exact quoted mentions in this snapshot, grouped by coded tone. Recent quotes are deduplicated and mixed across models.

What they recommend

“If I had to choose just one, **Zepbound (tirzepatide)** — here's why:”

“Zepbound: List price $1,086.37 per month; commercial insurance plus a manufacturer savings card can lower the cost to as little as $25 per month; Eli Lilly offers discounted pricing ranging from $299 to $699 per month.”

“Zepbound (tirzepatide injection): ~20% to 22.5% average weight loss (Zepbound targets two hormone pathways, GIP and GLP-1, whereas Foundayo only targets GLP-1).”

“Choose **Zepbound** (assuming your primary goal is chronic weight loss or weight management).”

“Often a strong option for weight reduction; FDA-approved for chronic weight management in adults with obesity, or overweight plus a weight-related condition.”

Where they hedge

“these two medications are approved for entirely different primary medical conditions and have different methods of use”

“the same ingredient is sold as **Zepbound** for chronic weight management”

“If you are looking for cheaper alternatives to Zepbound (tirzepatide)”

“tirzepatide is marketed as **Zepbound** for chronic weight management.”

“Zepbound costs about $1,060 per month with complete FDA oversight”

What they warn about

“**Wegovy** and **Zepbound** may be more effective for many people and are weekly rather than daily injections, but without coverage they are often still expensive.”

“Novo Nordisk is currently suing Eli Lilly over Zepbound ads. The ads compare Lilly's Zepbound with Novo's Wegovy, and Novo argues they give consumers a misleading picture of how the drugs compare”

“The dispute centers on dosing comparisons: Eli Lilly says its ads are based on the SURMOUNT-5 trial, completed in 2024, which compared patients on 10 or 15 milligrams of Zepbound to patients on 1.7 mg or 2.4 mg doses of Wegovy.”

The substitution map

Which competitors models suggest when shoppers ask for something cheaper.

Where this comes from

39 of 244 mentions appear alongside an identifiable web citation. Citation does not establish causation.

Where they send you

Stores and sites models name as places to buy this brand.

Method: fixed shopper questions asked repeatedly to Claude, OpenAI GPT and Gemini with web search on. Shares are the percentage of recommendation answers mentioning the brand. Quotes are AI outputs; full transcripts are kept as receipts.